Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
Clinical trial NCT07323056 · RECRUITING
Trial details
- NCT number
- NCT07323056
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-01
- Primary completion
- 2026-06-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.